JOHNSON & JOHNSON business relationships

Companies named in JOHNSON & JOHNSON’s 10-K filed 2026-02-11, and public companies whose annual reports name JOHNSON & JOHNSON. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.

Open on the map Full AI visibility profile

AEO visibility: 7.7 / 10
AI naming: 100 / 100
Agent readiness: 25 / 100
AI adoption: 0 / 100

Layers: Robotics

Named in JOHNSON & JOHNSON’s annual report 5

BayerPartner7.7
“...umber of products and compounds developed in collaboration with strategic partners including XARELTO, co-developed with Bayer HealthCare AG, IMBRUVICA, developed in collaboration and co-marketed with Pharmacyclics LLC, an AbbVie company and CARVYKTI, licensed and developed in collaboration with Lege...” SEC filing
GENMAB A/S (GMAB)Licensor6.1
“Separately, the Company has a number of licensing arrangements for products and compounds including DARZALEX, licensed from Genmab A/S.” SEC filing
Pharmacyclics LLCPartner5.4
“...ion with strategic partners including XARELTO, co-developed with Bayer HealthCare AG, IMBRUVICA, developed in collaboration and co-marketed with Pharmacyclics LLC, an AbbVie company and CARVYKTI, licensed and developed in collaboration with Legend Biotech USA Inc. and Legend Biotech Ireland Limited.” SEC filing
AbbVie Inc. (ABBV)Partner5.2
“...ion with strategic partners including XARELTO, co-developed with Bayer HealthCare AG, IMBRUVICA, developed in collaboration and co-marketed with Pharmacyclics LLC, an AbbVie company and CARVYKTI, licensed and developed in collaboration with Legend Biotech USA Inc. and Legend Biotech Ireland Limited.” SEC filing
Legend Biotech Corp (LEGN)Partner5.2
“...ion with strategic partners including XARELTO, co-developed with Bayer HealthCare AG, IMBRUVICA, developed in collaboration and co-marketed with Pharmacyclics LLC, an AbbVie company and CARVYKTI, licensed and developed in collaboration with Legend Biotech USA Inc. and Legend Biotech Ireland Limited.” SEC filing

Companies whose annual reports name JOHNSON & JOHNSON 26

BRISTOL MYERS SQUIBB CO (BMY)names it as partner7.7
“In cardiovascular diseases, the LIBREXIA clinical program, in partnership with Johnson & Johnson, includes registrational trials in atrial fibrillation and secondary stroke prevention for milvexian.” SEC filing
MATERIALISE NV (MTLS)names it as partner7.7
“In the medical market, we have entered into collaborations with DePuy Synthes Companies of Johnson & Johnson, or DePuy Synthes, and Zimmer Biomet Holdings, Inc., or Zimmer Biomet, as well as with Encore Medical, L.P. (d/b/a Enovis), or Enovis, Limacorporate Spa, or Lima, Mathys AG, or Mathys (which...” SEC filing
GENMAB A/S (GMAB)names it as licensee6.1
“In 2025 , royalties from Johnson & Johnson (" J&J "), legal entity Janssen Biotech, Inc., related to daratumumab” SEC filing
Pacira BioSciences, Inc. (PCRX)names it as partner6.1
“In July 2025, we entered into a co-promotion agreement with Johnson & Johnson MedTech, or J&J MedTech, (the "J&J Agreement"), to market and promote the use of ZILRETTA for OA knee pain in the U.S. J&J MedTech's specialized early intervention sales force will extend the reach of ZILRETTA beyond ortho...” SEC filing
BillionToOne, Inc. (BLLN)names it as partner5.5
“We have two strategic partnerships with Johnson & Johnson.” SEC filing
BillionToOne, Inc. (BLLN)names it as supplier5.5
“Final FDA approval of the companion diagnostics indication is dependent on the success of the Johnson & Johnson AZALEA Phase 3 clinical trial.” SEC filing
HARVARD BIOSCIENCE INC (HBIO)names it as customer5.4
“Our pharmaceutical and biotechnology customers include companies and research laboratories such as Abbott, Amgen, AstraZeneca, Bayer, Glaxo Smith Kline, Johnson & Johnson, Merck, Novartis, Pfizer and Regeneron.” SEC filing
MeiraGTx Holdings plc (MGTX)names it as licensor5.4
“...the sale of nonfinancial assets representing the sale and transfer of all the Company's right, title, and interest in the intellectual property related to the RPGR Product and the assignment of the UCLB RPGR License Agreement to Johnson & Johnson Innovative Medicine in the amount of $ 29.0 million.” SEC filing
MeiraGTx Holdings plc (MGTX)names it as partner5.4
“Under the Collaboration Agreement, Johnson & Johnson Innovative Medicine paid us a non-refundable upfront fee of $100.0 million in March 2019 and a milestone payment of $30.0 million in December 2021.” SEC filing
MeiraGTx Holdings plc (MGTX)names it as supplier5.4
“Our receipt of these milestones is dependent on Johnson & Johnson Innovative Medicine's ability to successfully develop and commercialize the RPGR Product and obtain the necessary regulatory approvals for its manufacturing facilities.” SEC filing
Nanobiotix S.A. (NBTX)names it as licensor5.4
“In July 2023, we entered into a global licensing agreement (Janssen Agreement) with Janssen Pharmaceutica NV ("Janssen"), a Johnson & Johnson” SEC filing
Protagonist Therapeutics, Inc (PTGX)names it as licensee5.4
“Icotyde is licensed to Janssen Biotech, Inc., a Johnson & Johnson company ("JNJ"), under a license and collaboration agreement initially entered into in 2017.” SEC filing
SUTRO BIOPHARMA, INC. (STRO)names it as licensor5.4
“In 2013, we and Johnson & Johnson Innovation, through the Johnson & Johnson Development Corporation, provided initial co-funding for Vaxcyte, with which we have a license agreement, a supply agreement, an option agreement and a manufacturing rights agreement related to certain development and manufa...” SEC filing
Kymera Therapeutics, Inc. (KYMR)names it as partner5.2
“In particular, several pharmaceutical companies have announced partnerships around programs targeting STAT6, including Sanofi, Johnson & Johnson and Gilead.” SEC filing
Legend Biotech Corp (LEGN)names it as licensor5.2
“In December 2017, the Company entered into a collaboration and license agreement (the "Janssen Agreement") with Janssen Biotech, Inc., a Johnson & Johnson company ("Janssen"), for the worldwide development and commercialization of cilta-cel.” SEC filing
Legend Biotech Corp (LEGN)names it as partner5.2
“• our ability to achieve specified milestones under our collaboration with Janssen Biotech, Inc., a Johnson & Johnson company ("Janssen") for cilta-cel or under other collaboration and license agreements we have entered into with other third parties;” SEC filing
Rallybio Corp (RLYB)names it as partner5.0
“Collaboration Agreement with Johnson & Johnson” SEC filing
Anika Therapeutics, Inc. (ANIK)names it as customer4.7
“The Company's largest such customer, Johnson & Johnson MedTech ("J&J MedTech") (previously known as DePuy Synthes Mitek Sports Medicine), a division of DePuy Orthopedics, Inc., part of the Johnson & Johnson Medical Companies, represented 50%, 57% and 62% of total revenues for the years-ended Decembe...” SEC filing
Anika Therapeutics, Inc. (ANIK)names it as licensor4.7
“Our license agreements with Johnson & Johnson MedTech ("J&J MedTech") provide substantial control of Monovisc and Orthovisc in the United States to J&J MedTech, and J&J MedTech's actions could have a material impact on our business, financial condition and results of operations.” SEC filing
Avalo Therapeutics, Inc. (AVTX)names it as licensor4.7
“...on upon the filing and acceptance of an NDA for AVTX-501 pursuant to an agreement with Janssen Pharmaceutics, Inc., now Johnson & Johnson Innovative Medicine ("J&J") (the "AVTX-501 Milestone") and (b) rights to any future milestone payments and royalties relating to AVTX-007 under a license agreemen...” SEC filing
Oric Pharmaceuticals, Inc. (ORIC)names it as partner4.7
“(1) Clinical collaboration with Johnson & Johnson to evaluate enozertinib in combination with SC amivantamab in patients with first-line NSCLC with EGFR exon 20 mutations.” SEC filing
Oric Pharmaceuticals, Inc. (ORIC)names it as supplier4.7
“We also announced that we entered into clinical trial collaboration and supply agreements with Johnson & Johnson and Bayer, to evaluate rinzimetostat in combination with Erleada® (apalutamide),” SEC filing
Caribou Biosciences, Inc. (CRBU)names it as partner4.2
“Autologous cell therapies directed at BCMA have been commercialized by Bristol-Myers Squibb Company (Abecma®) and Legend Biotech Corporation with their partner Johnson & Johnson (Carvykti®).” SEC filing
Contineum Therapeutics, Inc. (CTNM)names it as licensor4.2
“...2025, the Company has financed its operations primarily from the sale of equity securities and convertible equity securities, and a global license and development agreement (the "J&J License Agreement") the Company entered in February 2023 with Janssen Pharmaceutica NV, a Johnson & Johnson company.” SEC filing
GRAPHIC PACKAGING HOLDING CO (GPK)names it as customer3.5
“Health/beauty customers include GlaxoSmithKline, Bayer, Johnson & Johnson, Abbott, Novartis, L'Oréal S.A., Procter & Gamble and Colgate-Palmolive.” SEC filing
UNITED THERAPEUTICS Corp (UTHR)names it as supplier-
“Some of these therapies are manufactured and marketed by large pharmaceutical companies such as Johnson & Johnson, Gilead Sciences, Inc., Bayer Schering Pharma AG, GSK plc, and Merck, as well as a variety of large generic drug manufacturers.” SEC filing

Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.